Products - Multiple sclerosis | Topic | NICE

Showing 3 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Cladribine for treating relapsing multiple sclerosis [ID6263]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
9 January 2025
Expected publication date:
23 April 2025
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC